Sino Biopharmaceutical Limited commences an Equity Buyback Plan for 1,882,009,423 shares, representing 10% of its issued share capital, , under the authorization approved on June 6, 2022.

Sino Biopharmaceutical Limited (SEHK:1177) commences share repurchases on September 7, 2022, under the program mandated by the shareholders in the Annual General Meeting held on June 6, 2022. As per the mandate, the company is authorized to repurchase up to 1,882,009,423 shares, representing 10% of its issued share capital. The purpose of the program is to enhance the net asset value and/or earnings per share for the company.

The repurchases will be made out of the funds legally available for such purpose in accordance with its Bye-Laws and the applicable laws. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is carried out to the full extent, unless varied or revoked in a General Meeting. As of June 6, 2022, the company had 18,820,094,230 Shares in issue.